Quantitative and Visual Characteristics of Primary Central Nervous System Lymphoma on 18F-FDG-PET

被引:0
作者
Delin Liu
Ziren Kong
Yuekun Wang
Wenlin Chen
Yaning Wang
Wanqi Chen
Lei Liu
Yonghong Dang
Wenbin Ma
Yu Wang
Xin Cheng
机构
[1] Peking Union Medical College,Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
[2] Peking Union Medical College,Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
来源
Interdisciplinary Sciences: Computational Life Sciences | 2019年 / 11卷
关键词
F-FDG; Positron emission tomography; Lymphoma; Visual characteristic;
D O I
暂无
中图分类号
学科分类号
摘要
Primary central nervous system lymphomas (PCNSLs) are rare progressive brain tumors, whose managements are significantly different from other solid tumors, especially glioblastomas. Therefore, an early diagnosis is of great significance. 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET), which can measure the glucose metabolic rate in the brain, is an increasingly common tool for early diagnosis. Twenty-five immunocompetent patients with PCNSL were reviewed in this study to describe the general characteristics of PCNSL patients’ 18F-FDG-PET scans. Quantitative features included a radically enhanced maximum standardized uptake value (SUVmax) with a mean value of 23.8 ± 7.9 and a 5.8 ± 1.8 mean ratio of tumor-to-normal contralateral cortex activity (T/N). Visual characteristics, such as favored locations in the brain, lesion numbers, tumor shape, metabolic inhibition, and structural shift were determined as well. PCNSL was found to favor the cortex, especially the frontal lobe, followed by the basal ganglia and corpus callosum. All PCNSLs were near the lateral ventricular area. Tumor shapes were subdivided into three groups: diffuse, round, and irregular patterns. Reduced radiation was observed in the ipsilateral cortex, the basal ganglia and the contralateral cerebellum. The lateral ventricles were prone to be compressed on the side ipsilateral to the tumor, pushing the midline towards the contralateral side of the brain. In conclusion, aside from SUVmax and T/N values, other visual characteristics are also available to facilitate the differentiation of PCNSLs from other brain conditions on 18F-FDG-PET scans.
引用
收藏
页码:300 / 306
页数:6
相关论文
共 141 条
[1]  
Sierra del Rio M(2009)Primary CNS lymphoma in immunocompetent patients Oncologist 14 526-539
[2]  
Rousseau A(2008)Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment Leuk Lymphoma 49 43-51
[3]  
Soussain C(1997)Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature Ann Oncol 8 227-234
[4]  
Ricard D(2008)Primary central nervous system lymphoma Arch Pathol Lab Med 132 1830-1834
[5]  
Hoang-Xuan K(2002)Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging Radiology 223 11-29
[6]  
Rubenstein J(2011)Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging Am J Neuroradiol 32 507-514
[7]  
Ferreri AJM(2010)Differentiation among glioblastoma multiforme, solitary metastatic tumor, and lymphoma using whole-tumor histogram analysis of the normalized cerebral blood volume in enhancing and perienhancing lesions Am J Neuroradiol 31 1699-1706
[8]  
Pittaluga S(2009)Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging Radiology 251 467-475
[9]  
Reni M(2019)Imaging features (CT, MRI, MRS, and PET/CT) of primary central nervous system lymphoma in immunocompetent patients Neurol Sci 40 535-542
[10]  
Ferreri AJM(2011)Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study Ann Nucl Med 25 432-438